摘要
病毒性心肌炎发病机制仍不完全明确,治疗方法还在探索中。卡维地洛是一种新型的第三代β受体阻滞剂,具有β受体和α受体双重阻滞、调节细胞因子、抗氧化、抗心脏重构和抗心律失常等多方面的作用,通过减轻心肌炎症、延缓并逆转心室重构、改善血流动力学,从而减轻病毒性心肌炎病理生理改变,改善预后。目前关于卡维地洛治疗或干预病毒性心肌炎的报道日益增多,已逐渐受到重视。本文拟对卡维地洛治疗病毒性心肌炎机制的研究进展作一综述。
Carvedilol, a third-generation IS-blocker, can inhibit 15-receptor and or-receptor, regulate cytokine, has antioxidant, antiremodelling and antiarrhythmia ations and so on. It can attenuate inflammation, inhibit remodeling, improve hemodynamics and ameliorate prognosis of viral myocarditis. Now there have been more and more reports on the therapy of viral myocarditis with carvedilol. This article gives a review of research advances in mechanism of carvedilol in treatment of viral myocarditis.
出处
《国际药学研究杂志》
CAS
2007年第6期425-428,共4页
Journal of International Pharmaceutical Research
关键词
卡维地洛
心肌炎
心室重构
carvedilol
myocarditis
rentricular remodeling
